Enabling superior performance with 10X Genomics Single Cell Sequencing
LevitasBio has developed an innovative levitation technology platform which delivers a simple 3-step sample enrichment method. The LeviCellTM has been demonstrated to outperform standard processing in terms of cell viability, yield and most importantly the quality of single-cell results all in a fast and simple process that perfectly matched to any single cell workflow.
The simple three-step process streamlines the workflow and minimizes the risk of contamination and damage from multiple instances of handling and washing, consequently maximizing enrichment for each cell type. The LeviCellTM validated samples and cell types that can be found here.
Two dissociated primary tumor samples, an early and late stage bladder tumor, were used for the analysis. Both were obtained from Discovery Life Sciences (DLS). The samples were dissociated following DLS protocols.
To demonstrate the benefits of the LeviCellTM in removing dead cells and debris, each sample of 400k cells was split into fractions prior to the each enrichment process. One half of each sample was washed into a 10X library preparation buffer, while the other half was enriched for live cells using the LeviCellTM. After quantitation, the output from the LeviCellTM was put directly into the Chromium Next GEM single Cell 3’ kit step without additional washing. Approximately 15k cells were used for each method. Final cDNA concentration was estimated by BioAnalyzer. While all samples succeeded at this step, there was a clear improvement in quality of the cDNA and the results library quality from the material generated by the LeviCellTM.
All samples were normalized before library preparation to account for differences yields, after normalization 15K cells were loaded from each process into the Chromium system.
All samples were sequenced on the Illumina 6000 S2 sequencer to a depth of ~500 million read per sample. Sequencing metrics, including Q30 bases in reads, barcodes, and UMI’s were nearly identical across all samples. The fraction of reads mapped overall were very similar across all samples, and only small differences were observed in the fraction of reads mapping to intergenic, intronic, and exonic regions of the genome.
The most striking differences were seen when comparing the detected genes in the non-enriched sample to its corresponding live-enriched sample. This figure highlights the fact that the early stage bladder cancer had a nearly three-fold increase in the median number of genes detected per cell, while the late stage cancer sample showed a 50% increase.
Early Stage Cancer Sample
Late Stage Cancer Sample
The innovative label-free separation technology of the LeviCellTM facilitates complete debris and dead cell removal without affecting the original population representation of gene expression (please see our Population Representation application note for additional data on how the LeviCellTM maintains the original population representation). When it comes to single-cell study, purity and viability of cells harvested from the sample preparation stage is a determining factor for generating high quality data in downstream assays such as NGS (Next Generation Sequencing). The LeviCellTM’s ability to seamlessly enrich for target cells and produce robust yields of viable cells without preferentially depleting or changing the frequency or expression of cell types gives it the necessary technological characteristics that many scientists have been waiting for to take them to the next level.